Examining the Validity of Using a Gaussian Schell-Model Source To Model the Scattering of A Fully Coherent Gaussian Beam From A Rough Impedance Surface

Military applications that use adaptive optics (AO) often require a point source beacon at the target to measure and correct for wavefront aberrations introduced by atmospheric turbulence. However, turbulence prevents the formation of such a point beacon. The extended beacons that are created instead have finite spatial extents and exhibit varying degrees of spatial coherence. Modeling these extended beacons using a Gaussian Schell-model (GSM) form for the autocorrelation function would be a convenient approach due to the analytical tractability of Gaussian functions. We examine the validity of using such a model by evaluating the field scattered from a rough impedance surface using a full-wave computational technique called the method of moments (MoM). The MoM improves the fidelity of the analysis since it captures all the physics of the laser-target interaction, such as masking, shadowing, multiple reflections, etc. Two rough-surface targets with different roughness statistics are analyzed. The simulation results are verified with experimental bidirectional reflectance distribution function measurements. It is seen that for rough surfaces, in general, the scattered-field autocorrelation function is not of a GSM form. However, under certain conditions, modeling an extended beacon as a GSM source is legitimate. This analysis will aid in understanding the behavior of extended beacons and how they affect the overall performance of an AO system

Design, Development, and In-flight Testing of a Pointer/tracker for In-flight Experiments to Measure Aero-optical Effects over a Scaled Turret

We address the design, development, and testing of a pointer/tracker as a probe beam for the purpose of making high-speed, aero-optical measurements of the flow over a scaled beam director turret. The tracker uses retro-reflection of the probe beam off of a Reflexite annulus surrounding the turret. The constraints of the design required a near-total-commercial off the shelf system that could be quickly installed and removed in a rented aircraft. Baseline measurements of environmental vibrations are used to predict pointing performance; mitigation of line-of-sight jitter on the probe beam is achieved through passive isolation and the design of relay optics. Accommodation of ambient light is made with the use of wavelength filters and track algorithms. Postanalysis of measured data is compared to design estimates

XIPE: the X-ray Imaging Polarimetry Explorer

X-ray polarimetry, sometimes alone, and sometimes coupled to spectral and temporal variability measurements and to imaging, allows a wealth of physical phenomena in astrophysics to be studied. X-ray polarimetry investigates the acceleration process, for example, including those typical of magnetic reconnection in solar flares, but also emission in the strong magnetic fields of neutron stars and white dwarfs. It detects scattering in asymmetric structures such as accretion disks and columns, and in the so-called molecular torus and ionization cones. In addition, it allows fundamental physics in regimes of gravity and of magnetic field intensity not accessible to experiments on the Earth to be probed. Finally, models that describe fundamental interactions (e.g. quantum gravity and the extension of the Standard Model) can be tested. We describe in this paper the X-ray Imaging Polarimetry Explorer (XIPE), proposed in June 2012 to the first ESA call for a small mission with a launch in 2017 but not selected. XIPE is composed of two out of the three existing JET-X telescopes with two Gas Pixel Detectors (GPD) filled with a He-DME mixture at their focus and two additional GPDs filled with pressurized Ar-DME facing the sun. The Minimum Detectable Polarization is 14 % at 1 mCrab in 10E5 s (2-10 keV) and 0.6 % for an X10 class flare. The Half Energy Width, measured at PANTER X-ray test facility (MPE, Germany) with JET-X optics is 24 arcsec. XIPE takes advantage of a low-earth equatorial orbit with Malindi as down-link station and of a Mission Operation Center (MOC) at INPE (Brazil).Comment: 49 pages, 14 figures, 6 tables. Paper published in Experimental Astronomy http://link.springer.com/journal/1068

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

The Software Architecture and development approach for the ASTRI Mini-Array gamma-ray air-Cherenkov experiment at the Observatorio del Teide

The ASTRI Mini-Array is an international collaboration led by the Italian National Institute for Astrophysics (INAF) and devoted to the imaging of atmospheric Cherenkov light for very-high gamma-ray astronomy. The project is deploying an array of 9 telescopes sensitive above 1 TeV. In this contribution, we present the architecture of the software that covers the entire life cycle of the observatory, from scheduling to remote operations and data dissemination. The high-speed networking connection available between the observatory site, at the Canary Islands, and the Data Center in Rome allows for ready data availability for stereo triggering and data processing

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Adaptive Robust Control

National Science FoundationOpe

Comparison of Coherent and Incoherent Laser Beam Combination for Tactical Engagements

The performance of a multibeam laser system is evaluated for coherent and incoherent beam combination under tactical scenarios. For direct comparison, identical aperture geometries are used for both, coherent or incoherent, combination methods. The analysis assumes a multilaser source coupled with a conventional 0.32 m diameter, on-axis, beam director. Parametric analysis includes variations over residual errors, beam quality, atmospheric effects, and scenario geometry. Analytical solutions from previous results are used to evaluate performance for the vacuum case, providing an upper bound on performance and a backdrop for organizing the multitude of effects as they are analyzed. Wave optics simulations are used for total system performance. Each laser in the array has a wavelength of 1.07 μm, 10 kW (25 kW) output power, and Gaussian exitance profile. Both tracking and full-aperture adaptive optics are modeled. Three tactical engagement geometries, air to surface, surface to air, and surface to surface, are evaluated for slant ranges from 2.5 to 10 km. Two near-median atmospheric profiles were selected based upon worldwide climatological data. The performance metric used is beam propagation efficiency for circular target diameters of 5 and 10 cm.Abstract © SPI

Worldwide Uncertainty Assessments of Ladar and Radar Signal-To-Noise Ratio Performance for Diverse Low Altitude Atmospheric Environments

In this study of atmospheric effects on laser ranging and detection (ladar) and radar systems, the parameter space is explored using the Air Force Institute of Technology Center for Directed Energy\u27s (AFIT/CDE) High Energy Laser End-to-End Operational Simulation (HELEEOS) parametric one-on-one engagement level model. The expected performance of ladar systems is assessed at a representative wavelength of 1.557 µm at a number of widely dispersed land and maritime locations worldwide. Radar system performance is assessed at 95 GHz and 250 GHz. Scenarios evaluated include both down looking oblique and vertical engagement geometries over ranges up to 3000 meters in which clear air aerosols and thin layers of fog, locally heavy rain, and low stratus cloud types are expected to occur. Seasonal and boundary layer variations are considered to determine optimum employment techniques to exploit or defeat the environmental conditions. Each atmospheric particulate/obscurant/hydrometeor is evaluated based on its wavelength-dependent forward and off-axis scattering characteristics and absorption effects on system interrogation. Results are presented in the form of worldwide plots of notional signal to noise ratio. The ladar and 95 GHz system types exhibit similar SNR performance for forward oblique clear air operation. 1.557 µm ladar performs well for vertical geometries in the presence of ground fog, but has no near-horizontal performance under such meteorological conditions. It also has no performance if low altitude stratus is present. 95 GHz performs well for both the fog and stratus layer cases, for both vertical and forward oblique geometries. The 250 GHz radar system is heavily impacted by water vapor absorption in all scenarios studied; however it is not as strongly affected by clouds and fog as the 1.557 µm ladar. Locally heavy rain will severely limit ladar system performance at these wavelengths. However, under heavy rain conditions ladar outperforms both radar systems. © 2013 SPI